← All indications
Sclerosis
A pathological process consisting of hardening or fibrosis of an anatomical structure, often a vessel or a nerve.
Drugs by status
Phase 4 trials (7)
Phase 3 trials (23)
- nitrous oxide
- methylprednisolone
- brodalumab
- urea
- cannabidiol
- leuprolide
- lymphocyte immune globulin, anti-thymocyte globulin (equine)
- amlodipine
- iloprost
- pirfenidone
- lidocaine
- cyclophosphamide
- everolimus
- ramipril
- live, attenuated, dengue serotype 1, 2, 3, 4 virus
- autologous mononuclear stem cell
- metoprolol
- rituximab
- oxygen
- sargramostim
- prilocaine
- abobotulinumtoxinA
- lerodalcibep
Phase 2 trials (47)
- abituzumab
- allogeneic natural killer cells
- bleselumab
- brentuximab vedotin
- ccx-140
- tofacitinib
- cxa-10
- prednisone
- doxorubicin
- gc1008
- obinutuzumab
- tacrolimus
- ifx-1
- nivolumab
- bleomycin
- ixazomib
- belumosudil
- pembrolizumab
- ly3090106
- rimabotulinumtoxinB
- allogeneic hematopoietic stem cells
- selexipag
- mycophenolate
- vinblastine
- alprostadil
- cd19 car-t cells
- pf-06730512
- allogeneic bone marrow
- methotrexate
- fludarabine
- +17 more
Phase 1 trials (24)
Organizations
Organization Involved with Phase 4 Indications (110)
- New York University
- University of Turku
- Genzyme
- University of Washington
- Mallinckrodt
- State University of New York
- University of Michigan
- Elan Pharmaceuticals
- Government of Mexico
- Novartis
- University of Genoa
- Washington University in St. Louis
- Regina Berkovich MD, PhD Inc.
- University of New Mexico
- EvergreenHealth
- National University of Ireland
- MidAmerica Research Foundation
- Ospedale Regionale di Lugano
- Forest Laboratories
- Johns Hopkins University
- Sanofi
- GB Pharma Services & Consulting S.r.l.
- University of Medicine and Dentistry of New Jersey
- Nema Research
- Pfizer
- Merck
- Instituto Mexicano del Seguro Social
- Erasmus University Rotterdam
- Merck KGaA
- University Clermont Auvergne
- +80 more
Organization Involved with Phase 3 Indications (264)
- Mercy Multiple Sclerosis Center of Oklahoma Mercy Neuroscience Institute
- Corbus Pharmaceuticals Inc.
- Italian Multiple Sclerosis Foundation
- National Taiwan University
- Hampton Roads Neurology
- Region Syddanmark
- Universidad Autonoma de Nuevo Leon
- Japan Agency for Medical Research and Development
- National Cancer Institute (NCI)
- Ospedale Civile di Chivasso
- Rivermead Rehabilitation Centre
- Vestre Viken Ringerike Sykehus
- National Center for Research Resources (NCRR)
- Central Texas Neurology Consultants
- University of Paris
- The Avicena Group
- Osmotica Pharmaceutical
- Unifour Medical Research, LLC
- University of Southern California
- MonitorCRO
- Macquarie University
- Multiple Sclerosis Society of Canada
- Universidad Autonoma de Madrid
- Advanced Neurology Specialists
- University of Verona
- Eisai
- Weleda AG
- University of Padova
- ALS Society of Canada
- Danske Regioner
- +234 more
Organization Involved with Phase 2 Indications (289)
- Calvary Health Care Bethlehem
- Andalusian Initiative for Advanced Therapies
- Vicore Pharma AB
- Umea University
- Novo Cellular Medicine Institute LLP
- Gunma University
- Knopp Neurosciences Inc.
- PDL BioPharma
- Agenzia Italiana del Farmaco
- Inventiva Pharma
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Danish Research Centre for Magnetic Resonance
- Northeast ALS Consortium
- Aucta Pharms
- INC Research
- Implicit Bioscience
- inVentiv
- Corestem, Inc.
- University of Zurich
- RemeGen
- Clinica Universidad de Navarra
- Nanjing University
- Innobioscience SpA
- Sangamo BioSciences
- University of Utah
- Stem Cells Arabia
- IQVIA
- Multiple Sclerosis Institute
- University of Malaya
- University of Florida
- +259 more
Organization Involved with Phase 1 Indications (67)
- University of Antwerp
- AL-S Pharma
- Fondazione Cellule Staminali
- Spanish National Health System
- Hackensack University Medical Center
- New York Medical College
- DJO Incorporated
- Atara Biotherapeutics
- Deutsches Zentrum für Neurodegenerative Erkrankungen e. V.
- BBB Therapeutics
- Alliance Foundation Trials
- University of Illinois at Chicago
- Rapa Therapeutics LLC
- Aptiv Solutions
- Brain Health Alliance
- Apitope
- François Rabelais University
- Casa Sollievo della Sofferenza IRCCS
- Fondazione Italiana Sclerosi Multipla
- Case Western Reserve University
- Pavlov First Saint Petersburg State Medical University
- Repligen Corporation
- Cognitive Research Corporation
- BfARM, Bonn
- Society for Pediatric Dermatology
- Radboud University
- University of Bonn
- Universidad de Murcia
- University of Queensland
- Centre for Probe Development and Commercialization
- +37 more
Organization Involved with Other Experimental Indications (37)
- iReportoire Inc
- Mandell Center for Multiple Sclerosis
- Orbis Medical Centre
- Hasselt University
- University of Tuebingen
- Elysium Health
- Campus Bio-Medico University
- University of Novi Sad
- Catholic University of Korea
- Region of Southern Denmark
- University of Florence
- The Augustinus Foundation, Denmark.
- University of Valencia
- CryoHoldco LATAM
- Saint Francis Hospital and Medical Center
- Zhejiang University
- Nanjing 1718 Biotech Co. Ltd
- Universidad de la Sabana
- Jiangsu University
- Fundación Neumologica Colombiana
- Tanner Center for MS
- D'Annunzio University of Chieti–Pescara
- The Foundation of Lily Benthine Lund
- Avera Health
- Tanner Foundation for Multiple Sclerosis
- Cerecin
- Dalian Medical University
- Sun Yat-Sen University
- CarnoMed
- Kessler Medical Rehabilitation Research and Education Corporation
- +7 more